microRNA在急性肾损伤与肾移植中的作用
本文综述microRNA作为表观遗传调控因子在急性肾损伤和肾移植中的病理生理作用及生物标志物价值。microRNA在血浆和尿液中稳定性好,但现有临床研究结果多不明确,需标准化并在前瞻性试验中验证。
要点
- microRNA参与细胞间通讯和器官间交互,失调与肾脏疾病相关。
- 血浆和尿液中的microRNA稳定性好,具备生物标志物潜力。
- 现有临床证据多不明确,需标准化和前瞻性试验确认。
核心结论
- microRNA在急性肾损伤和肾移植中具有病理生理作用和生物标志物潜力,但临床证据尚不明确,需标准化和前瞻性验证。
研究设计与样本
- 综述,总结microRNA在急性肾损伤和肾移植中病理生理与生物标志物领域的通用概念和现有临床证据。
主要发现
- microRNA是转录后水平的表观遗传调控因子,参与细胞间通讯和器官间交互。
- microRNA失调与包括肾脏疾病在内的多种疾病相关。
- microRNA在血浆和尿液中稳定性显著,使其成为有吸引力的生物标志物。
- 近几十年肾脏病学临床microRNA研究聚焦于发现特定microRNA特征及识别治疗和/或疾病预防的新靶点。
- 许多研究结果不明确,需要标准化和前瞻性试验确认。
局限性
- 许多临床microRNA研究结果不明确。
- 需要标准化和前瞻性试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MicroRNAs are epigenetic regulators of gene expression at the posttranscriptional level. They are involved in intercellular communication and crosstalk between different organs. As key regulators of homeostasis, their dysregulation underlies several morbidities including kidney disease. Moreover, their remarkable stability in plasma and urine makes them attractive biomarkers. Beyond biomarker studies, clinical microRNA research in nephrology in recent decades has focused on the discovery of specific microRNA signatures and the identification of novel targets for therapy and/or disease prevention. However, much of this research has produced equivocal results and there is a need for standardization and confirmation in prospective trials. This review aims to provide an overview of general concepts and available clinical evidence in both the pathophysiology and biomarker fields for the role of microRNA in AKI and kidney transplantation.
引用
- Ledeganck KJ, Gielis EM, Abramowicz D, et al. MicroRNAs in AKI and Kidney Transplantation. Clin J Am Soc Nephrol. 2019. PMID: 30602462. doi:10.2215/CJN.08020718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。